CA3226898A1 - Ibudilast for preventing eye cancer metastasis - Google Patents
Ibudilast for preventing eye cancer metastasis Download PDFInfo
- Publication number
- CA3226898A1 CA3226898A1 CA3226898A CA3226898A CA3226898A1 CA 3226898 A1 CA3226898 A1 CA 3226898A1 CA 3226898 A CA3226898 A CA 3226898A CA 3226898 A CA3226898 A CA 3226898A CA 3226898 A1 CA3226898 A1 CA 3226898A1
- Authority
- CA
- Canada
- Prior art keywords
- day
- ibudilast
- cancer
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163225820P | 2021-07-26 | 2021-07-26 | |
| US63/225,820 | 2021-07-26 | ||
| PCT/US2022/038157 WO2023009425A1 (en) | 2021-07-26 | 2022-07-25 | Ibudilast for preventing eye cancer metastasis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3226898A1 true CA3226898A1 (en) | 2023-02-02 |
Family
ID=82851760
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3226898A Pending CA3226898A1 (en) | 2021-07-26 | 2022-07-25 | Ibudilast for preventing eye cancer metastasis |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US12005049B2 (https=) |
| EP (1) | EP4376838A1 (https=) |
| JP (1) | JP2024528731A (https=) |
| CN (1) | CN117940128A (https=) |
| CA (1) | CA3226898A1 (https=) |
| WO (1) | WO2023009425A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12005049B2 (en) | 2021-07-26 | 2024-06-11 | Medicinova, Inc. | Methods of preventing cancer metastasis |
| US12042485B2 (en) | 2021-10-07 | 2024-07-23 | Medicinova, Inc. | Methods of minimizing cancer metastasis |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6395747B1 (en) | 1998-08-10 | 2002-05-28 | Sauro Sakoda | Remedies for multiple sclerosis |
| JP4954085B2 (ja) | 2004-12-06 | 2012-06-13 | メディシノバ， インコーポレイテッド | 神経障害性疼痛及びその関連する症状を治療するためのイブジラスト |
| US8138201B2 (en) | 2007-07-11 | 2012-03-20 | Medicinova, Inc. | Treatment of progressive neurodegenerative disease with ibudilast |
| EP2858635A1 (en) * | 2012-06-11 | 2015-04-15 | The Regents of The University of California | Inhibitors of hippo-yap signaling pathway |
| KR102462638B1 (ko) | 2014-11-26 | 2022-11-03 | 메디시노바, 인크. | 이부딜라스트와 릴루졸의 배합물 및 이의 사용방법 |
| WO2018119262A1 (en) | 2016-12-22 | 2018-06-28 | Medicinova, Inc. | Methods of treating glioblastoma multiforme using ibudilast |
| ES2959799T3 (es) | 2018-02-12 | 2024-02-28 | Medicinova Inc | Métodos para suprimir células supresoras de origen mieloide en pacientes |
| JP2021512921A (ja) | 2018-02-12 | 2021-05-20 | メディシノバ・インコーポレイテッドＭｅｄｉｃｉＮｏｖａ， Ｉｎｃ． | 癌療法に対するイブジラストおよび第二の薬剤を使用した方法ならびに投与レジメン |
| WO2020076809A1 (en) | 2018-10-09 | 2020-04-16 | Medicinova, Inc. | Combination of ibudilast and interferon-beta and methods of using same |
| CN112804999B (zh) | 2018-10-19 | 2024-03-15 | 美迪诺亚公司 | 通过异丁司特治疗眼科疾病/病症或损伤的方法 |
| EP4034090A1 (en) | 2019-09-23 | 2022-08-03 | MediciNova, Inc. | Ibudilast oral formulations and methods of using same |
| CA3174413A1 (en) | 2020-04-06 | 2021-10-14 | Yuichi Iwaki | Methods of reducing plasma level of macrophage migratory inhibitory factor in patients with ibudilast |
| WO2022164948A1 (en) | 2021-01-29 | 2022-08-04 | Medicinova, Inc. | Methods of treating chemical gas exposure |
| US12005049B2 (en) | 2021-07-26 | 2024-06-11 | Medicinova, Inc. | Methods of preventing cancer metastasis |
| CA3231869A1 (en) | 2021-09-21 | 2023-03-30 | Medicinova, Inc. | Ibudilast in combination therapy for use in the treatment of glioblastoma |
| US12042485B2 (en) | 2021-10-07 | 2024-07-23 | Medicinova, Inc. | Methods of minimizing cancer metastasis |
| CN118973574A (zh) | 2022-02-01 | 2024-11-15 | 美迪诺亚公司 | 异丁司特治疗新冠肺炎后遗症的用途 |
-
2022
- 2022-07-25 US US17/872,855 patent/US12005049B2/en active Active
- 2022-07-25 JP JP2024505211A patent/JP2024528731A/ja active Pending
- 2022-07-25 WO PCT/US2022/038157 patent/WO2023009425A1/en not_active Ceased
- 2022-07-25 CA CA3226898A patent/CA3226898A1/en active Pending
- 2022-07-25 EP EP22754252.9A patent/EP4376838A1/en active Pending
- 2022-07-25 CN CN202280059689.8A patent/CN117940128A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US12005049B2 (en) | 2024-06-11 |
| CN117940128A (zh) | 2024-04-26 |
| US20230037014A1 (en) | 2023-02-02 |
| EP4376838A1 (en) | 2024-06-05 |
| JP2024528731A (ja) | 2024-07-30 |
| WO2023009425A1 (en) | 2023-02-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0616344A2 (pt) | mÉtodo para o tratamento de dependÊncia quÍmica e comportamental | |
| JP2023120445A (ja) | テルリプレシン組成物およびその使用方法 | |
| US10391085B2 (en) | Methods of treating glioblastoma multiforme using ibudilast | |
| US12005049B2 (en) | Methods of preventing cancer metastasis | |
| US11446283B2 (en) | Methods and dosing regimens using ibudilast and a second agent for cancer therapy | |
| CA3174413A1 (en) | Methods of reducing plasma level of macrophage migratory inhibitory factor in patients with ibudilast | |
| US20210177812A1 (en) | Methods of suppressing myeloid-derived suppressor cells in patients | |
| US12171752B2 (en) | Methods of treating post-COVID condition(s) | |
| US11865214B2 (en) | Ibudilast oral formulations and methods of using same | |
| WO2008057496A2 (en) | Method for treating delirium | |
| US12042485B2 (en) | Methods of minimizing cancer metastasis | |
| JP2023529764A (ja) | 下気道障害の処置 | |
| CA3231869A1 (en) | Ibudilast in combination therapy for use in the treatment of glioblastoma | |
| US20220241252A1 (en) | Methods of treating chemical gas exposure | |
| JP2024517694A (ja) | インターロイキン－１受容体アンタゴニストの組成物 | |
| HK40111880A (zh) | 低剂量纳曲醇和其用途 | |
| HK40014065A (en) | Terlipressin composition for use in treating ascites | |
| HK40014065B (en) | Terlipressin composition for use in treating ascites |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250603 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250603 |